IN2015DN00502A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN00502A IN2015DN00502A IN502DEN2015A IN2015DN00502A IN 2015DN00502 A IN2015DN00502 A IN 2015DN00502A IN 502DEN2015 A IN502DEN2015 A IN 502DEN2015A IN 2015DN00502 A IN2015DN00502 A IN 2015DN00502A
- Authority
- IN
- India
- Prior art keywords
- infections
- diabetes
- inflammation
- cancer
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76024106P | 2006-01-18 | 2006-01-18 | |
PCT/IB2007/002542 WO2007138485A2 (en) | 2006-01-18 | 2007-01-18 | Ppar modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN00502A true IN2015DN00502A (pt) | 2015-06-26 |
Family
ID=38779054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN502DEN2015 IN2015DN00502A (pt) | 2006-01-18 | 2007-01-18 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20110178112A1 (pt) |
EP (2) | EP1976509B1 (pt) |
JP (3) | JP2009523781A (pt) |
CN (3) | CN101657099B (pt) |
AU (1) | AU2007266714B2 (pt) |
CA (1) | CA2637803A1 (pt) |
DK (1) | DK1976509T3 (pt) |
ES (1) | ES2533652T3 (pt) |
IN (1) | IN2015DN00502A (pt) |
MX (1) | MX2008009241A (pt) |
PL (1) | PL1976509T3 (pt) |
RU (1) | RU2449999C2 (pt) |
WO (1) | WO2007138485A2 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008089461A1 (en) * | 2007-01-18 | 2008-07-24 | Evolva Sa | Substituted 1,3-dioxanes useful as ppar modulators |
ES2609825T3 (es) * | 2007-01-18 | 2017-04-24 | Evolva Sa | 1,3-Dioxanos sustituidos útiles como moduladores de PPAR |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2011057262A2 (en) * | 2009-11-09 | 2011-05-12 | Evolva Inc. | Treatment of infections with tp receptor antagonists |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013068486A1 (en) | 2011-11-08 | 2013-05-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of male infertility |
US10415054B2 (en) * | 2013-02-04 | 2019-09-17 | Eth Zurich | Designer circuit controlling diet-induced obesity |
CN106687506A (zh) * | 2014-07-03 | 2017-05-17 | 莫门蒂夫性能材料股份有限公司 | 酯官能的聚硅氧烷和由其制成的共聚物 |
US20210113613A1 (en) * | 2017-08-02 | 2021-04-22 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating cancer |
RU2674987C1 (ru) * | 2018-04-17 | 2018-12-14 | Акционерное общество "Всесоюзный научный центр по безопасности биологически активных веществ" АО "ВНЦ БАВ" | 2-Аминия-7-(диэтиламино)-4-(4-метоксибензо[d][1,3]диоксол-5-ил)-4Н-хромен-3-карбонитрила N-ацетиламиноэтаноат, проявляющий противоопухолевую активность |
US20220331267A1 (en) * | 2019-09-05 | 2022-10-20 | Rush University Medical Center | Methods and compositions for treatment of demyelinating disorders |
PL4000615T3 (pl) | 2020-11-13 | 2022-12-19 | Serodus Asa | Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerek |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU540462A1 (ru) * | 1975-07-21 | 1977-06-25 | Научно-Исследовательский Институт Онкологии Им.Профессора Н.Н.Петрова Министерства Здравохранения Ссср | 5,5-Дизамещенные 2-(4-бис-(2-хлорэтил)аминофенил)-1,3-диоксаны, обладающие противоопухолевой активностью |
GB8310407D0 (en) * | 1982-05-12 | 1983-05-25 | Ici Plc | 1 3 - dioxan -5- ylalkenoic acids |
GB8330120D0 (en) * | 1983-11-11 | 1983-12-21 | Ici Plc | Chemical process |
GB8511890D0 (en) | 1985-05-10 | 1985-06-19 | Ici Plc | Benzene derivatives |
DE3685775T2 (de) * | 1985-05-10 | 1993-01-21 | Ici Plc | Alkenderivate. |
GB8626297D0 (en) * | 1986-11-04 | 1986-12-03 | Ici Plc | Pharmaceutical compositions |
GB8901201D0 (en) * | 1988-02-16 | 1989-03-15 | Ici Plc | Pyridine derivatives |
US5248780A (en) * | 1988-02-16 | 1993-09-28 | Imperial Chemical Industries, Plc | Pyridyl substituted alkenoic acid derivatives |
IE81170B1 (en) * | 1988-10-21 | 2000-05-31 | Zeneca Ltd | Pyridine derivatives |
US5128359A (en) * | 1990-02-16 | 1992-07-07 | Laboratoires Upsa | Benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists, their methods of preparation |
ZA911453B (en) * | 1990-03-19 | 1991-11-27 | Squibb & Sons Inc | Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation |
SI9300097B (en) * | 1992-02-27 | 2001-12-31 | Janssen Pharmaceutica Nv | (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines |
US5462726A (en) * | 1993-12-17 | 1995-10-31 | Bristol-Myers Squibb Company | Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents |
US5801195A (en) * | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
EP0832295A1 (en) | 1995-06-07 | 1998-04-01 | Ligand Pharmaceuticals Incorporated | Method for screening for receptor agonists and antagonists |
WO1997010813A1 (en) | 1995-09-18 | 1997-03-27 | Ligand Pharmaceuticals Incorporated | Ppar gamma antagonists for treating obesity |
GB9600464D0 (en) | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
WO1998043081A1 (en) | 1997-03-26 | 1998-10-01 | Ligand Pharmaceuticals Incorporated | Treatment of gastrointestinal disease with ppar modulators |
US5981586A (en) | 1997-05-23 | 1999-11-09 | Pershadsingh; Harrihar A. | Methods for treating proliferative and inflammatory skin diseases |
US6410245B1 (en) | 1998-04-01 | 2002-06-25 | Affymax, Inc. | Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions |
US6277884B1 (en) * | 1998-06-01 | 2001-08-21 | Nitromed, Inc. | Treatment of sexual dysfunction with N-hydroxyguanidine compounds |
US6436997B1 (en) * | 1998-06-01 | 2002-08-20 | Nitromed, Inc. | Endogenous nitric oxide synthesis under conditions of low oxygen tension |
US6509348B1 (en) * | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
AU1179000A (en) * | 1998-11-19 | 2000-06-13 | Shionogi & Co., Ltd. | Preventives and/or remedies for central nervous system diseases containing compounds having TXA2 receptor antagonism and/or TXA2 synthase inhibitory effect |
US6291496B1 (en) | 1999-12-27 | 2001-09-18 | Andrew J. Dannenberg | Treating cancers associated with overexpression of class I family of receptor tyrosine kinases |
US6284790B1 (en) * | 2000-06-15 | 2001-09-04 | Sachin Gupte | Methods of potentiating organic nitrates having vasodilating activity and formulations for the same |
CA2427774C (en) * | 2000-11-09 | 2013-01-15 | The Hospital For Sick Children | Inhibitors of thromboxane formation and action |
US20030175349A1 (en) * | 2001-01-30 | 2003-09-18 | Council Of Scientific And Industrial Research | Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient |
AU4755502A (en) | 2001-06-14 | 2002-12-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Cofactor-based screening method for nuclear receptor modulators and related modulators |
WO2004052876A1 (en) * | 2002-12-12 | 2004-06-24 | Janssen Pharmaceutica, N.V. | Substituted 4-phenyl-[1,3]-dioxanes |
WO2004060282A2 (en) * | 2002-12-19 | 2004-07-22 | Synaptic Pharmaceutical Corporation | Uses of the snorf207 receptor |
-
2007
- 2007-01-18 RU RU2008133416/04A patent/RU2449999C2/ru not_active IP Right Cessation
- 2007-01-18 US US12/161,317 patent/US20110178112A1/en not_active Abandoned
- 2007-01-18 IN IN502DEN2015 patent/IN2015DN00502A/en unknown
- 2007-01-18 AU AU2007266714A patent/AU2007266714B2/en not_active Ceased
- 2007-01-18 EP EP07804876.6A patent/EP1976509B1/en not_active Not-in-force
- 2007-01-18 MX MX2008009241A patent/MX2008009241A/es active IP Right Grant
- 2007-01-18 WO PCT/IB2007/002542 patent/WO2007138485A2/en active Application Filing
- 2007-01-18 CA CA002637803A patent/CA2637803A1/en not_active Abandoned
- 2007-01-18 ES ES07804876.6T patent/ES2533652T3/es active Active
- 2007-01-18 PL PL07804876T patent/PL1976509T3/pl unknown
- 2007-01-18 JP JP2008550880A patent/JP2009523781A/ja active Pending
- 2007-01-18 EP EP11166139A patent/EP2363127A1/en not_active Withdrawn
- 2007-01-18 DK DK07804876T patent/DK1976509T3/en active
-
2008
- 2008-01-18 CN CN200880008902.2A patent/CN101657099B/zh active Active
- 2008-01-18 CN CN200880008866A patent/CN101646344A/zh active Pending
- 2008-01-18 CN CN200880008956A patent/CN101657100A/zh active Pending
-
2012
- 2012-12-28 JP JP2012286467A patent/JP2013060465A/ja not_active Withdrawn
-
2014
- 2014-03-24 US US14/223,621 patent/US20140288110A1/en not_active Abandoned
-
2015
- 2015-07-15 JP JP2015141004A patent/JP2015180703A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
CN101657099A (zh) | 2010-02-24 |
AU2007266714B2 (en) | 2013-03-14 |
DK1976509T3 (en) | 2015-03-23 |
AU2007266714A1 (en) | 2007-12-06 |
US20140288110A1 (en) | 2014-09-25 |
ES2533652T3 (es) | 2015-04-13 |
JP2009523781A (ja) | 2009-06-25 |
RU2008133416A (ru) | 2010-02-27 |
US20110178112A1 (en) | 2011-07-21 |
EP1976509A2 (en) | 2008-10-08 |
EP2363127A1 (en) | 2011-09-07 |
CA2637803A1 (en) | 2007-12-06 |
WO2007138485A3 (en) | 2008-04-24 |
PL1976509T3 (pl) | 2015-07-31 |
CN101657099B (zh) | 2014-11-26 |
RU2449999C2 (ru) | 2012-05-10 |
MX2008009241A (es) | 2008-10-20 |
EP1976509B1 (en) | 2014-12-17 |
CN101657100A (zh) | 2010-02-24 |
WO2007138485A2 (en) | 2007-12-06 |
CN101646344A (zh) | 2010-02-10 |
JP2013060465A (ja) | 2013-04-04 |
JP2015180703A (ja) | 2015-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN00502A (pt) | ||
CY1121135T1 (el) | Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος | |
SG165362A1 (en) | Ppar active compounds | |
MX2009001327A (es) | Compuestos de indol. | |
WO2006127900A3 (en) | Tl1a in the treatment of disease | |
CL2007003155A1 (es) | Compuestos derivados de 3,7-diazabiciclo[3.3.0]octano o 3,7-diazabiciclo[3.3.1]nonano, moduladores de receptores nicotinicos neuronales; composicion farmaceutica; y uso en el tratamiento de trastornos del snc. | |
HK1124552A1 (en) | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases | |
WO2009071690A3 (de) | 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen | |
WO2009071689A3 (de) | 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen | |
TNSN08400A1 (en) | Organic compounds and their uses | |
EP2069377A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND SKIN FUNCTIONAL DISORDERS | |
NO20055098D0 (no) | Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser | |
WO2007144057A3 (en) | Antimicrobial carbon | |
WO2006125813A3 (en) | Tetrahydropyridothiophenes for use in the treatment of cancer | |
WO2006125815A3 (en) | Tetrahydropyridothiophenes for use in the treatment of cancer | |
EP1865954A4 (en) | METHOD FOR AVOIDING OEDEM IN THE TREATMENT OR PREVENTION OF DISEASES AFFECTING PPAR GAMMA INCLUDING CANCER | |
WO2008090209A3 (en) | Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders | |
WO2007133983A3 (en) | 2-aminobenzimidazoles for treating neurodegenerative diseases | |
ATE511512T1 (de) | Olanzapinpamoat-dihydrat | |
UA99901C2 (en) | Indole compounds | |
DK1713438T3 (da) | Medicinsk sæbe | |
WO2006116076A3 (en) | Tab molecules | |
WO2007012066A3 (en) | TRUNCATED OXIDIZED THYMOSIN β4 AND DERIVATIVES THEREOF | |
GEP20104911B (en) | Medicinal agent for preventing progression of apoptotic and jugulating necrotic changes in the organism tissues | |
TW200616651A (en) | Mussel extract composition with enhanced anti-inflammatory activity |